Reimagining cholinergic therapy for Alzheimer’s disease

The cholinergic hypothesis of geriatric memory dysfunction

Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · see citing works

SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

Coyle, J. T., Price, D. L., & DeLong, M. R. (1983) · Science · doi:10.1126/science.6338589 · Cited by 3,050 · see citing works

Diagnosis and Treatment of Parkinson Disease: A Review

Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924 · see citing works

Comprehensive Review on Alzheimer’s Disease: Causes and Treatment

Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · see citing works

Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · see citing works

Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

(2018) · Neurology · doi:10.1212/wnl.0000000000004826 · Cited by 2,183 · see citing works

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Perry, E., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P., & Perry, R. H. (1978) · British medical journal · doi:10.1136/bmj.2.6150.1457 · Cited by 2,043 · see citing works

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease

Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · see citing works

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · see citing works

The role of acetylcholine in learning and memory

Hasselmo, M. E. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.09.002 · Cited by 1,693 · see citing works

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560 · see citing works

Pharmacological Treatment of Parkinson Disease

Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,510 · see citing works

NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES

Bowen, D. M., Smith, C. B., White, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,313 · see citing works

Donepezil for dementia due to Alzheimer’s disease.

Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200 · see citing works

Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type

Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K. H., & Kling, A. S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152001 · Cited by 1,161 · see citing works

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · see citing works

Sex differences in Alzheimer disease — the gateway to precision medicine

for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009 · see citing works

Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors

Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898 · see citing works

Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment

Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., & Mufson, E. J. (2007) · Neurology · doi:10.1212/01.wnl.0000260698.46517.8f · Cited by 824 · see citing works

Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline

Ballinger, E. C., Ananth, M. R., Talmage, D. A., & Role, L. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.006 · Cited by 735 · see citing works

A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer disease

Appel, S. H. (1981) · Annals of Neurology · doi:10.1002/ana.410100602 · Cited by 698 · see citing works

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

Bodick, N. C., Offen, W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 687 · see citing works

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment

DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · see citing works

The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study

Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2004) · Brain · doi:10.1093/brain/awh067 · Cited by 675 · see citing works

Clinical trials and late‐stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works

Anticholinergic Drug Exposure and the Risk of Dementia

Coupland, C. A. C., Hill, T., Dening, T., Morriss, R. K., Moore, M. V., & Hippisley‐Cox, J. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0677 · Cited by 619 · see citing works

Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease

Bohnen, N. I., Kaufer, D., Ivanco, L. S., Lopresti, B. J., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 551 · see citing works

Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration

Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543 · see citing works

Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase

Mesulam, M. M., & Geula, C. (1988) · The Journal of Comparative Neurology · doi:10.1002/cne.902750205 · Cited by 520 · see citing works

The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients with Dementia of the Alzheimer Type

Sahakian, B. J., Jones, G., Levy, R., Gray, J. A., & Warburton, D. M. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.6.797 · Cited by 494 · see citing works

Alzheimer disease therapy—moving from amyloid-β to tau

Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 483 · see citing works

The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease.

Fahnestock, M., Michalski, B., Xu, B., & Coughlin, M. (2001) · Molecular and cellular neurosciences · doi:10.1006/mcne.2001.1016 · Cited by 482 · see citing works

Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease

Jönhagen, M. E., Nordberg, A. K., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. A., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472 · see citing works

The Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?

Mesulam, M. (2004) · Learning &amp; Memory · doi:10.1101/lm.69204 · Cited by 467 · see citing works

The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions

Dunnett, S. B., Everitt, B. J., & Robbins, T. W. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90061-x · Cited by 460 · see citing works

Quantitative assessment of cortical synaptic density in Alzheimer's disease

Scheff, S. W., DeKosky, S. T., & Price, D. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90059-9 · Cited by 446 · see citing works

Handbook Of Behavioral Neuroscience

(2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(08)00237-3 · Cited by 425 · see citing works

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418 · see citing works

M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice

Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., & LaFerla, F. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.020 · Cited by 417 · see citing works

Sex and the development of Alzheimer's disease

Pike, C. J. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23827 · Cited by 405 · see citing works

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

Winblad, B. G., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68350-5 · Cited by 388 · see citing works

Dementia in Parkinson disease

Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Wd, H. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 383 · see citing works

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383 · see citing works

Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease

Mesulam, M. M. (2013) · The Journal of Comparative Neurology · doi:10.1002/cne.23415 · Cited by 378 · see citing works

Cholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum

Mesulam, M. M., Shaw, P. L., Mash, D. C., & Weıntraub, S. (2004) · Annals of Neurology · doi:10.1002/ana.20100 · Cited by 365 · see citing works

Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains

Nordberg, A. K., & Winblad, B. G. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90629-4 · Cited by 361 · see citing works

Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease

Levey, A. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13541 · Cited by 359 · see citing works

Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade

Bruno, M. A., & Cuello, A. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510645103 · Cited by 344 · see citing works

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

Brannan, S. K., Sawchak, S. T., Miller, A., Lieberman, J. A., Paul, S. M., & Breier, A. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2017015 · Cited by 343 · see citing works

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Fortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30689-9 · Cited by 340 · see citing works

Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: Lesion effects in the rat brain and levels in Alzheimer's disease

Goedert, M., Fine, A., Hunt, S. P., & Ullrich, A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90023-9 · Cited by 338 · see citing works

Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion

Cooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · see citing works

The pedunculopontine tegmental nucleus: Where the striatum meets the reticular formation

Inglis, W. L., & Winn, P. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00013-l · Cited by 335 · see citing works

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Feldman, H., Ferris, S. H., Winblad, B. G., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A. S., Cummings, J. L., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335 · see citing works

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology

Schmitz, T. W., Spreng, R. N., Initiative, T. A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 335 · see citing works

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · see citing works

A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease

Lozano, A. M., Fosdick, L., Chakravarty, M. M., Leoutsakos, J., Munro, C. A., Oh, E. S., Drake, K. E., Lyman, C. H., Rosenberg, P. B., Anderson, W. S., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160017 · Cited by 329 · see citing works

Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report)

Olson, L., Nordberg, A. K., von Holst, H., Bäckman, L., Ebendal, T., Alafuzoff, I. I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257624 · Cited by 323 · see citing works

Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials

Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040338 · Cited by 322 · see citing works

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

Henderson, E. J., Lord, S. R., Brodie, M. A. D., Gaunt, D., Lawrence, A. D., Close, J., Whone, A. L., & Ben‐Shlomo, Y. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00389-0 · Cited by 304 · see citing works

Efficacy of donepezil in mild cognitive impairment

Salloway, S., Ferris, S. H., Kluger, A., Goldman, R. S., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300 · see citing works

Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus

Volpicelli‐Daley, L. A., & Levey, A. I. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)45003-6 · Cited by 299 · see citing works

Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease

Tuszynski, M. H., Yang, J. H., Barba, D., U, H.-S., Bakay, R. A. E., Pay, M. M., Masliah, E., Conner, J. M., Kobalka, P., Roy, S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1807 · Cited by 287 · see citing works

Donepezil for dementia due to Alzheimer's disease

Birks, J., & Harvey, R. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub2 · Cited by 285 · see citing works

Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease

Grothe, M. J., Heinsen, H., & Teipel, S. J. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.06.019 · Cited by 283 · see citing works

Activation of the genetically defined m1 muscarinic receptor potentiates N -methyl- d -aspartate (NMDA) receptor currents in hippocampal pyramidal cells

Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., & Conn, P. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11465 · Cited by 275 · see citing works

Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease

Doraiswamy, P. M., Leon, J., Cummings, J. L., Marin, D. B., & Neumann, P. J. (2002) · The Journals of Gerontology Series A · doi:10.1093/gerona/57.3.m173 · Cited by 270 · see citing works

Safety and efficacy of galantamine in subjects with mild cognitive impairment

Winblad, B. G., Gauthier, S. G., Scinto, L. F. M., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 267 · see citing works

Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type

Iversen, L. L., Rossor, M. N., Reynolds, G. P., Hills, R., Roth, M., Mountjoy, C. Q., Foote, S. L., Morrison, J. H., & Bloom, F. E. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90171-4 · Cited by 264 · see citing works

Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease

Quiroz, Y. T., Budson, A. E., Celone, K., Ruiz‐Rizzo, A. L., Newmark, R. E., Castrillón, G., Lopera, F. J., & Stern, C. E. (2010) · Annals of Neurology · doi:10.1002/ana.22105 · Cited by 251 · see citing works

MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

Dickerson, B. C., & Wolk, D. A. (2011) · Neurology · doi:10.1212/wnl.0b013e31823efc6c · Cited by 243 · see citing works

Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study

Kilimann, I., Grothe, M. J., Heinsen, H., Alho, E. J. L., Grinberg, L. T., Amaro, E., dos Santos, G. A. B., da Silva, R. E., Mitchell, A. J., Frisoni, G. B., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132345 · Cited by 239 · see citing works

Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease

Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.6.641 · Cited by 236 · see citing works

Effects of Estrogen Replacement on the Relative Levels of Choline Acetyltransferase, trkA, and Nerve Growth Factor Messenger RNAs in the Basal Forebrain and Hippocampal Formation of Adult Rats

Gibbs, R. B., Wu, D., Hersh, L. B., & Pfaff, D. W. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1148 · Cited by 233 · see citing works

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

Kandiah, N., Pai, M.-C., Senanarong, V., Looi, I., Ampil, E. R., Park, K. W., Karanam, A. K., & Christopher, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s129145 · Cited by 232 · see citing works

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

Perry, E. K., Kilford, L., Lees, A. J., Burn, D. J., & Perry, R. H. (2003) · Annals of Neurology · doi:10.1002/ana.10639 · Cited by 229 · see citing works

Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB

Sahakian, B. J., Owen, A. M., Morant, N. J., Eagger, S. A., Boddington, S., Crayton, L., Crockford, H. A., Crooks, M., Hill, K., & Levy, R. (1993) · Psychopharmacology · doi:10.1007/bf02244644 · Cited by 226 · see citing works

CSF biomarkers predict a more malignant outcome in Alzheimer disease

Wallin, A., Blennow, K., Zetterberg, H., Londos, E., Minthon, L., & Hansson, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dd4dd8 · Cited by 223 · see citing works

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease

Maelicke, A., & Albuquerque, E. X. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00093-5 · Cited by 222 · see citing works

Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV

Aghourian, M., Legault-Denis, C., Soucy, J.-P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., & Bédard, M.-A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.183 · Cited by 220 · see citing works

Choline-esterase. An enzyme present in the blood-serum of the horse

Stedman, E., Stedman, E., & Easson, L. H. (1932) · Biochemical Journal · doi:10.1042/bj0262056 · Cited by 217 · see citing works

Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease

Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215 · see citing works

The anatomy of the CNS cholinergic neurons

Cuello, A. C., & Sofroniew, M. V. (1984) · Trends in Neurosciences · doi:10.1016/s0166-2236(84)80161-7 · Cited by 212 · see citing works

Noradrenergic dysfunction in Alzheimer's disease

Gannon, M. A., Che, P., Chen, Y., Jiao, K., Roberson, E. D., & Wang, Q. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00220 · Cited by 211 · see citing works

Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease

Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211 · see citing works

Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients

Štorga-Tomić, D., Vrečko, K., Birkmayer, J. G. D., & Reibnegger, G. J. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12256-7 · Cited by 209 · see citing works

Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease

Schulz, J., Pagano, G., Bonfante, J. A. F., Wilson, H., & Politis, M. (2018) · Brain · doi:10.1093/brain/awy072 · Cited by 209 · see citing works

In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease

Ray, N. J., Bradburn, S., Murgatroyd, C., Toseeb, U., Mir, P., Kountouriotis, G., Teipel, S. J., & Grothe, M. J. (2017) · Brain · doi:10.1093/brain/awx310 · Cited by 208 · see citing works

The role of noradrenaline in cognition and cognitive disorders

Holland, N., Robbins, T. W., & Rowe, J. B. (2021) · Brain · doi:10.1093/brain/awab111 · Cited by 201 · see citing works

Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes

Wong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196 · see citing works

DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL

Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 194 · see citing works

Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert

Sassin, I., Schultz, C., Thal, D. R., Rüb, U., Arai, K., Braak, E., & Braak, H. (2000) · Acta Neuropathologica · doi:10.1007/s004019900178 · Cited by 193 · see citing works

ALZHEIMER-LIKE CHOLINERGIC DEFICIENCY IN DOWN SYNDROME

Yates, C. M., Simpson, J., Maloney, A. F. J., Gordon, A., & Reid, A. H. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92137-6 · Cited by 190 · see citing works

Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease.

Mufson, E., Lavine, N., Jaffar, S., Kordower, J., Quirion, R., & Saragovi, H. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6504 · Cited by 188 · see citing works

α7 Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide-induced Tau Protein Phosphorylation

Wang, H.-Y., Li, W., Benedetti, N. J., & Lee, D. H. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212532200 · Cited by 185 · see citing works

The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease

Nordström, P., Religa, D., Wimo, A. B., Winblad, B. G., & Eriksdotter, M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht182 · Cited by 184 · see citing works

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality

Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011832 · Cited by 182 · see citing works

Effects of Cholinergic Enhancement on Visual Stimulation, Spatial Attention, and Spatial Working Memory

Bentley, P., Masud Husain, B., & Dolan, R. J. (2004) · Neuron · doi:10.1016/s0896-6273(04)00145-x · Cited by 179 · see citing works

Cholinesterase inhibitors for mild cognitive impairment

Russ, T. C., & Morling, J. R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009132.pub2 · Cited by 179 · see citing works

The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor

Fahnestock, M. L., Yu, G., Michalski, B., Mathew, S., Colquhoun, A., Ross, G. M., & Coughlin, M. D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02360.x · Cited by 173 · see citing works

Hippocampal plasticity during the progression of Alzheimer’s disease

Mufson, E. J., Mahady, L. J., Waters, D., Counts, S., Perez, S. E., DeKosky, S. T., Ginsberg, S. D., Ikonomović, M. D., Scheff, S. W., & Binder, L. I. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.006 · Cited by 172 · see citing works

Extrinsic Sources of Cholinergic Innervation of the Striatal Complex: A Whole-Brain Mapping Analysis

Dautan, D., Bay, H. H., Bolam, J. P., Gerdjikov, T. V., & Mena‐Segovia, J. (2016) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2016.00001 · Cited by 172 · see citing works

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses

Rogers, Cooper, Sukovaty, Pederson, Lee, & Friedhoff (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.0460s1007.x · Cited by 171 · see citing works

Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects

Bohnen, N. I., Albin, R. L., Müller, M. L. T. M., Petrou, M., Kotagal, V., Koeppe, R. A., Scott, P. J. H., & Frey, K. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2757 · Cited by 167 · see citing works

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses

Howard, R. J., McShane, R. H., Lindesay, J. E. B., Ritchie, C. W., Baldwin, A., Barber, R., Burns, A. S., Dening, T., Findlay, D. M., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 164 · see citing works

Pro-NGF Isolated from the Human Brain Affected by Alzheimer's Disease Induces Neuronal Apoptosis Mediated by p75NTR

Pedraza, C. E., Podlesniy, P., Vidal, N., Arévalo, J. C., Lee, R., Hempstead, B. L., Ferrer, I., Iglesias, M., & Espinet, C. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62275-4 · Cited by 164 · see citing works

Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment

Bruno, M. A., Mufson, E. J., Wuu, J., & Cuello, A. C. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c22569 · Cited by 163 · see citing works

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease

Bohnen, N. I. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.038729 · Cited by 160 · see citing works

Cholinesterase inhibitors increase secretion of APPs in rat brain cortex

Mori, F., Lai, C.-C., Fusi, F., & Giacobini, E. (1995) · Neuroreport · doi:10.1097/00001756-199503000-00012 · Cited by 157 · see citing works

Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists

Mirza, N. R., Peters, D., & Sparks, R. G. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00247.x · Cited by 155 · see citing works

Clinical trials in mild cognitive impairment: lessons for the future

Jelić, V. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072926 · Cited by 155 · see citing works

The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease

Beach, T. G., Kuo, Y., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 153 · see citing works

Cholinergic Treatments with Emphasis on M1 Muscarinic Agonists as Potential Disease-Modifying Agents for Alzheimer's Disease

Fisher, A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.002 · Cited by 151 · see citing works

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

Janicki, S. C., & Schupf, N. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0122-6 · Cited by 150 · see citing works

Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review

Repantis, D., Laisney, O., & Heuser, I. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.02.009 · Cited by 150 · see citing works

Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease

Bruno, M. A., León, W., Fragoso, G., Mushynski, W. E., Almazán, G., & Cuello, A. C. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181aed9e6 · Cited by 148 · see citing works

Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment

Bell, K. F. S., Bennett, D. A., & Cuello, A. C. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3269-07.2007 · Cited by 145 · see citing works

Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus

Dennis, S. H., Pasqui, F., Colvin, E. M., Sanger, H., Mogg, A. J., Felder, C. C., Broad, L. M., Fitzjohn, S. M., Isaac, J. T. R., & Mellor, J. R. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv227 · Cited by 144 · see citing works

The α-Secretase-derived N-terminal Product of Cellular Prion, N1, Displays Neuroprotective Function in Vitro and in Vivo

Guillot‐Sestier, M., Sunyach, C., Druon, C., Scarzello, S., & Checler, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051086 · Cited by 143 · see citing works

Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease

Fisher, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 140 · see citing works

Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease

Dubois, B., Marie Chupin, A., Hampel, H. J., Lista, S., Cavedo, E., Croisile, B., Louis-Tisserand, G., Touchon, J., Bonafé, A., Ousset, P., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 140 · see citing works

Activation of m 1 Muscarinic Acetylcholine Receptor Regulates τ Phosphorylation in Transfected PC12 Cells

Sadot, E., Gurwitz, D., Barg, J., Behar, L., Ginzburg, I., & Fisher, A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020877.x · Cited by 139 · see citing works

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease

MacGowan, S. H., Wilcock, G. K., & Scott, M. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199809)13:9 · Cited by 139 · see citing works

Regional Effects of Donepezil and Rivastigmine on Cortical Acetylcholinesterase Activity in Alzheimer’s Disease

Kaasinen, V., Någren, K., Järvenpää, T., Roivainen, A., Yu, M., Oikonen, V., Kurki, T. J. I., & Rinne, J. O. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00012 · Cited by 138 · see citing works

Deletion of M ₁ Muscarinic Acetylcholine Receptors Increases Amyloid Pathology <i>In Vitro</i> and <i>In Vivo</i>

Davis, A. A., Fritz, J. J., Wess, J., Lah, J. J., & Levey, A. I. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6393-09.2010 · Cited by 137 · see citing works

Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome

Iulita, M. F., & Cuello, A. C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.010 · Cited by 135 · see citing works

Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia

Miller, R. J., & Chouinard, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90044-e · Cited by 133 · see citing works

The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease

Deardorff, W. J., Feen, E. S., & Grossberg, G. T. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0273-x · Cited by 129 · see citing works

Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease

Höck, C., Heese, K., Müller-Spahn, F., Hulette, C., Rosenberg, C. K., & Otten, U. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00019-6 · Cited by 126 · see citing works

Down syndrome and beta-amyloid deposition

Head, E., & Lott, I. T. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200404000-00003 · Cited by 125 · see citing works

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer&amp;rsquo;s disease

Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125 · see citing works

Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years

Wattmo, C., & Wallin, Å. K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0294-2 · Cited by 125 · see citing works

Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer’s Dementia: An Update

Hoskin, J. L., Al-Hasan, Y. M., & Sabbagh, M. N. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty116 · Cited by 123 · see citing works

Mitogen‐Activated Protein Kinase‐Dependent and Protein Kinase C‐Dependent Pathways Link the m1 Muscarinic Receptor to β‐Amyloid Precursor Protein Secretion

Haring, R., Fisher, A., Marciano, D., Pittel, Z., Kloog, Y., Zuckerman, A., Eshhar, N., & Heldman, E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052094.x · Cited by 122 · see citing works

Loss of Muscarinic M1 Receptor Exacerbates Alzheimer's Disease–Like Pathology and Cognitive Decline

Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto‐Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., Fisher, A., & LaFerla, F. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.041 · Cited by 120 · see citing works

Cholinergic Involvement in Alzheimer’s Disease. A Link with NGF Maturation and Degradation

Cuello, A. C., Bruno, M. A., Allard, S., León, W., & Iulita, M. F. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9238-z · Cited by 119 · see citing works

Cholinergic augmentation modulates visual task performance in sleep-deprived young adults

Chuah, L. Y. M., & Chee, M. W. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4045-08.2008 · Cited by 118 · see citing works

A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat

Debeir, T., Saragovi, H. U., & Cuello, A. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.4067 · Cited by 114 · see citing works

Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders

Babiloni, C., Cassetta, E., Forno, G. D., Percio, C. D., Ferreri, F., Ferri, R., Lanuzza, B., Miniussi, C., Moretti, D. V., Nobili, F. M., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.02.015 · Cited by 111 · see citing works

Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease

Höck, C., Maddalena, A. S., Raschig, A., Müller-Spahn, F., Eschweiler, G. W., Huger, K., Hewer, I., Hampel, H. J., Müller-Thornsen, T., Oertel, W. H., et al. (2003) · Amyloid · doi:10.3109/13506120308995249 · Cited by 110 · see citing works

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

Verma, S., Kumar, A., Tripathi, T., & Kumar, A. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12919 · Cited by 110 · see citing works

Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease

Cavedo, E., Grothe, M. J., Colliot, O., Lista, S., Marie Chupin, A., Dormont, D., Houot, M., Lehéricy, S., Teipel, S. J., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 109 · see citing works

The Brain NGF Metabolic Pathway in Health and in Alzheimer’s Pathology

Cuello, A. C., Pentz, R., & Hall, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00062 · Cited by 108 · see citing works

Pharmacological Management of Dementia with Lewy Bodies

Hershey, L. A., & Coleman-Jackson, R. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00636-7 · Cited by 108 · see citing works

Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis

Matsunaga, S., Fujishiro, H., & Takechi, H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190546 · Cited by 108 · see citing works

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET

Shinotoh, H., Aotsuka, A., Fukushi, K., Nagatsuka, S., Tanaka, N., Ota, T., Tanada, S., & Irie, T. (2001) · Neurology · doi:10.1212/wnl.56.3.408 · Cited by 105 · see citing works

Further understanding the connection between Alzheimer's disease and Down syndrome

Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12112 · Cited by 105 · see citing works

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105 · see citing works

PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD

Kadir, A., Darreh‐Shori, T., Almkvist, O., Wall, A., Grut, M., Strandberg, B., Ringheim, A., Eriksson, B., Blomquist, G., Långström, B., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.020 · Cited by 103 · see citing works

Cardiovascular Effects of Drugs Used to Treat Alzheimer’s Disease

Howes, L. G. (2014) · Drug Safety · doi:10.1007/s40264-014-0161-z · Cited by 102 · see citing works

Use of Muscarinic Agonists in the Treatment of Sjögren's Syndrome

Fox, R. I., Konttinen, Y. T., & Fisher, A. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5128 · Cited by 101 · see citing works

Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex.

Fahnestock, M., Scott, S., Jette, N., Weingartner, J. A., & Crutcher, K. (1996) · Brain Research. Molecular Brain Research · doi:10.1016/s0169-328x(96)00193-3 · Cited by 101 · see citing works

Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype

Allard, S., León, W., Pakavathkumar, P., Bruno, M. A., Ribeiro‐da‐Silva, A., & Cuello, A. C. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1144-11.2012 · Cited by 101 · see citing works

Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling

Angelastro, J. M., Klimaschewski, L. P., Tang, S., Vitolo, O. V., Weissman, T. A., Donlin, L. T., Shelanski, M. L., & Greene, L. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10424 · Cited by 100 · see citing works

An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation

Iulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99 · see citing works

Longitudinal Alzheimer’s Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections

Schmitz, T. W., Mur, M., Aghourian, M., Bédard, M., & Spreng, R. N. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.001 · Cited by 98 · see citing works

Taking Pain Out of NGF: A “Painless” NGF Mutant, Linked to Hereditary Sensory Autonomic Neuropathy Type V, with Full Neurotrophic Activity

Capsoni, S., Covaceuszach, S., Marinelli, S., Ceci, M., Bernardo, A., Minghetti, L., Ugolini, G., Pavone, F., & Cattaneo, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017321 · Cited by 97 · see citing works

Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans

Furey, M. L., Pietrini, P., Alexander, G. E., Schapiro, M. B., & Horwitz, B. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00219-1 · Cited by 95 · see citing works

Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: Effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration

Venero, J. L., Knüsel, B., Beck, K. D., & Hefti, F. F. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90285-2 · Cited by 94 · see citing works

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Wattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93 · see citing works

Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease

Giacobini, E. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_17 · Cited by 91 · see citing works

Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases

Felder, C. C., Goldsmith, P., Jackson, K. A., Sanger, H., Evans, D. A. P., Mogg, A. J., & Broad, L. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.028 · Cited by 91 · see citing works

Sex and gender differences in the treatment of Alzheimer’s disease: A systematic review of randomized controlled trials

Canevelli, M., Quarata, F., Remiddi, F., Lucchini, F., Lacorte, E., Vanacore, N., Bruno, G., & Cesari, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.035 · Cited by 88 · see citing works

Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3β inhibition and in neurons

Forlenza, O. V., Spink, J. M., Dayanandan, R., Anderton, B. H., Olesen, O. F., & Lovestone, S. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070034 · Cited by 85 · see citing works

Cholinesterase inhibitors for mild cognitive impairment

Russ, T. C., & Morling, J. R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009132 · Cited by 85 · see citing works

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting

Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · see citing works

Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease

Iulita, M. F., Millón, M. B. B., Pentz, R., Aguilar, L. F., Carmo, S. D., Allard, S. T. M., Michalski, B., Wilson, E. N., Ducatenzeiler, A., Bruno, M. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.08.019 · Cited by 84 · see citing works

Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status

Choi, S. H., Jung, T.-M., Lee, J. E., Lee, S., Sohn, Y. H., & Lee, P. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.015 · Cited by 83 · see citing works

Increased Levels of Tau Protein in SH‐SY5Y Cells After Treatment with Cholinesterase Inhibitors and Nicotinic Agonists

Hellström‐Lindahl, E., Moore, H., & Nordberg, A. K. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740777.x · Cited by 81 · see citing works

Predictors of long-term cognitive outcome in Alzheimer's disease

Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt85 · Cited by 81 · see citing works

Therapeutic Strategies in Alzheimer’s Disease: Ml Muscarinic Agonists

Fisher, A. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.84.101 · Cited by 80 · see citing works

AF150(S) and AF267B

Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 80 · see citing works

Runaway synaptic modification in models of cortex: Implications for Alzheimer's disease

Hasselmo, M. E. (1994) · Neural Networks · doi:10.1016/0893-6080(94)90053-1 · Cited by 80 · see citing works

M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition

Moran, S. P., Dickerson, J. W., Cho, H. P., Xiang, Z., Maksymetz, J., Remke, D. H., Lv, X., Doyle, C. A., Rajan, D. H., Niswender, C. M., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0033-9 · Cited by 79 · see citing works

A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

Farlow, M. R., Grossberg, G. T., Sadowsky, C., Meng, X., & Somogyi, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12158 · Cited by 78 · see citing works

Cholinergic Stimulation Enhances Neural Activity Associated with Encoding but Reduces Neural Activity Associated with Retrieval in Humans

Kukolja, J., Thiel, C., & Fink, G. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0203-09.2009 · Cited by 77 · see citing works

Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease

Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., Neumaier, B., Fink, G. R., & Kukolja, J. (2018) · Brain · doi:10.1093/brain/awx356 · Cited by 77 · see citing works

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors

Giacobini, E., & Pepeu, G. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180613111504 · Cited by 77 · see citing works

Intermittent Stimulation of the Nucleus Basalis of Meynert Improves Working Memory in Adult Monkeys

Liu, R., Crawford, J., Callahan, P. M., Terry, A. V., Constantinidis, C., & Blake, D. T. (2017) · Current Biology · doi:10.1016/j.cub.2017.07.021 · Cited by 76 · see citing works

Older patients are still under-represented in clinical trials of Alzheimer's disease

Banzi, R., Camaioni, P., Tettamanti, M., Bertele’, V., & Lucca, U. (2016) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-016-0201-2 · Cited by 74 · see citing works

Parkinson's Disease Dementia and Lewy Body Disease

Sezgi̇n, M., Bılgıç, B., Tinaz, S., & Emre, M. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678579 · Cited by 74 · see citing works

Donepezil Improves Episodic Memory in Young Individuals Vulnerable to the Effects of Sleep Deprivation

Chuah, L. Y. M., Chong, D., Chen, A. K., Rekshan, W. R., Tan, J.-C., Zheng, H., & Chee, M. W. L. (2009) · SLEEP · doi:10.1093/sleep/32.8.999 · Cited by 73 · see citing works

Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease

Al-Shaikh, F. S. H., Duara, R., Crook, J., Lesser, E. R., Schaeverbeke, J., Hinkle, K., Ross, O., Ertekin-Taner, N., Pedraza, O., Dickson, D., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3606 · Cited by 73 · see citing works

M1 muscarinic receptor activation protects neurons from β-amyloid toxicity. A role for Wnt signaling pathway

Farı́as, G. G., Godoy, J. A., Hernández, F., Ávila, J., Fisher, A., & Inestrosa, N. C. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.016 · Cited by 72 · see citing works

Do Cholinesterase Inhibitors Have Disease-Modifying Effects in Alzheimer??s Disease?

Giacobini, E. (2001) · CNS Drugs · doi:10.2165/00023210-200115020-00001 · Cited by 72 · see citing works

Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum

Messamore, E. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90114-i · Cited by 72 · see citing works

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors

Parnetti, L., Amici, S., Lanari, A., Romani, C., Antognelli, C., Andreasen, N., Minthon, L., Davidsson, P., Pottel, H., Blennow, K., et al. (2002) · Neurological Sciences · doi:10.1007/s100720200086 · Cited by 72 · see citing works

M1 Agonists for the Treatment of Alzheimer's Disease.

Fisher, A., Heldman, E., Gurwitz, D., Haring, R., Karton, Y., Meshulam, H., Pittel, Z., Marciano, D., Brandeis, R., Sadot, E., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34418.x · Cited by 71 · see citing works

M1 Muscarinic Agonist Treatment Reverses Cognitive and Cholinergic Impairments of Apolipoprotein E‐Deficient Mice

Fisher, A., Brandeis, R., Chapman, S., Pittel, Z., & Michaelson, D. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051991.x · Cited by 70 · see citing works

Selective pathological changes of the periaqueductal gray matter in Alzheimer's disease

Parvizi, J., Hoesen, G. W. V., & Damásio, A. R. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 70 · see citing works

Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease

Mucha, L., Wang, S. S., Cuffel, B. J., McRae, T. D., Mark, T. L., & del Valle, M. C. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.5.451 · Cited by 70 · see citing works

Modifying the progression of Alzheimer's and Parkinson's disease with deep brain stimulation.

Jakobs, M., Lee, D. J., & Lozano, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107860 · Cited by 68 · see citing works

The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease

Pentz, R., Iulita, M. F., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0797-2 · Cited by 68 · see citing works

The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer’s Disease

Cuello, A. C., & Bruno, M. A. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9270-0 · Cited by 67 · see citing works

The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease

Iulita, M. F., & Cuello, A. C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100030 · Cited by 67 · see citing works

Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists

Beach, T. G., Walker, D. G., Potter, P. E., Sue, L. I., & Fisher, A. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02484-2 · Cited by 66 · see citing works

Treatment of Mild Cognitive Impairment (MCI)

Farlow, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929282 · Cited by 66 · see citing works

NGF mRNA is not decreased in frontal cortex from Alzheimer's Disease patients

Jetté, N., Cole, M., & Fahnestock, M. L. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90159-7 · Cited by 66 · see citing works

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works

Brain energy metabolism: A roadmap for future research

Rae, C. D., Baur, J. A., Borges, K., Dienel, G. A., Díaz‐García, C. M., Douglass, S. R., Drew, K. L., Duarte, J. M. N., Durán, J., Kann, O., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16032 · Cited by 109 · see citing works

Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations

Hossain, M. S., & Hussain, M. H. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70131 · Cited by 94 · see citing works

Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing

Orlando, I. F., Shine, J. M., Robbins, T. W., Rowe, J. B., & O’Callaghan, C. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105167 · Cited by 77 · see citing works

Pathophysiology of Alzheimer’s Disease

Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: relevance for precision medicine in neurodegenerative diseases

Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 46 · see citing works

Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?

Høilund‐Carlsen, P. F., Alavi, A. A., Castellani, R. J., Neve, R. L., Perry, G. L., Revheim, M.-E. R., & Barrio, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073892 · Cited by 41 · see citing works

Sex‐specific declines in cholinergic‐targeting tRNA fragments in the nucleus accumbens in Alzheimer's disease

Shulman, D., Dubnov, S., Zorbaz, T., Madrer, N., Paldor, I., Bennett, D. A., Seshadri, S. S., Mufson, E. J., Greenberg, D., Loewenstein, Y., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13095 · Cited by 38 · see citing works

Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review

Pozzi, F. E., Conti, E., Appollonio, I., Ferrarese, C., & Tremolizzo, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.998224 · Cited by 36 · see citing works

Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab

Chin, E., Jaqua, E. E., Safaeipour, M., & Ladue, T. (2022) · Cureus · doi:10.7759/cureus.31065 · Cited by 35 · see citing works

Mechanistic Insights, Treatment Paradigms, and Clinical Progress in Neurological Disorders: Current and Future Prospects

Alkahtani, S. H., AL–Johani, N. S., & Alarifi, S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021340 · Cited by 32 · see citing works

Application of biomarker-derived fluorescent probes for the detection of Alzheimer's disease

Ding, H., Li, Z., Luo, K., Gong, Q., & Tian, X. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117369 · Cited by 30 · see citing works

Discovery of novel butyrylcholinesterase inhibitors for treating Alzheimer's disease

Sang, Z., Huang, S., Tan, W., Ban, Y., Wang, K., Fan, Y., Chen, H., Zhang, Q., Liang, C., Mi, J., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.030 · Cited by 30 · see citing works

Apelin-13-Mediated Upregulation of METTL3 Ameliorates Alzheimer’s Disease via Inhibiting Neuroinflammation Through m6A-Dependent Regulation of lncRNA BDNF-AS

Han, L., Wei, S., Wang, R., Liu, Y., Zhong, Y., Fu, J., Luo, H., & Bao, M. (2025) · Biomolecules · doi:10.3390/biom15081188 · Cited by 29 · see citing works

The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy

Wang, T., & Jia, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512025 · Cited by 29 · see citing works

Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective

Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 30 · see citing works

Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies

Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 32 · see citing works

Landscape of immune infiltration in entorhinal cortex of patients with Alzheimerʼs disease

Zhang, H., Cao, S., Xu, Y., Sun, X., Fei, M., Jing, Q., Xu, X., Tang, J., Niu, B., & Li, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.941656 · Cited by 27 · see citing works

Adrenergic regulation of astroglial aerobic glycolysis and lipid metabolism: Towards a noradrenergic hypothesis of neurodegeneration

Zorec, R., & Vardjan, N. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106132 · Cited by 26 · see citing works

L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review

Wang, W., Pan, D., Liu, Q., Chen, X., & Wang, S. (2024) · Nutrients · doi:10.3390/nu16081232 · Cited by 27 · see citing works

Cell-type-specific optogenetic fMRI on basal forebrain reveals functional network basis of behavioral preference

Zou, Y., Tong, C., Peng, W., Qiu, Y., Li, J., Xia, Y., Pei, M., Zhang, K., Li, W., Xu, M., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.017 · Cited by 24 · see citing works

Distinct septo-hippocampal cholinergic projections separately mediate stress-induced emotional and cognitive deficits

Jian-lin, W., Li, Z.-M., Chen, H. H., Chen, W., Hu, N.-Y., Jin, S.-Y., Li, X., Chen, Y., Yang, J., & Gao, T. (2024) · Science Advances · doi:10.1126/sciadv.ado1508 · Cited by 24 · see citing works

Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis

Sowmiya, S., Ls, D., Rajendran, P., Harikrishnan, N., & Ankul Singh, S. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.11.004 · Cited by 22 · see citing works

Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer’s disease

Yu, C., Liu, X., Ma, B., Xu, J., Chen, Y., Dai, C., Peng, H., & Zha, D. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2313682 · Cited by 22 · see citing works

The Advancements of Marine Natural Products in the Treatment of Alzheimer’s Disease: A Study Based on Cell and Animal Experiments

Jia, C., Chai, J., Zhang, S., Sun, Y., He, L., Sang, Z., Chen, D., & Zheng, X. (2025) · Marine Drugs · doi:10.3390/md23030091 · Cited by 21 · see citing works

Design, synthesis, and biological evaluation of novel capsaicin-tacrine hybrids as multi-target agents for the treatment of Alzheimer's disease

Long, J., Qin, F., Luo, J., Zhong, G., Huang, S., Jing, L., Yi, T., Liu, J., & Jiang, N. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107026 · Cited by 21 · see citing works

Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease

Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 22 · see citing works

The potential anti-Alzheimer's activity of Oxalis corniculata Linn. Methanolic extract in experimental rats: Role of APOE4/LRP1, TLR4/NF-κβ/NLRP3, Wnt 3/β-catenin/GSK-3β, autophagy and apoptotic cues

Abu‐Elfotuh, K., Hamdan, A. M., Mohamed, S. A., Bakr, R. O., Ahmed, A. H., Atwa, A. M., Hamdan, A. M., Alanzai, A. G., Alnahhas, R. K., Gowifel, A. M. H., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117731 · Cited by 20 · see citing works

The new perspective of Alzheimer's Disease Research: Mechanism and therapeutic strategy of neuronal senescence

Niu, Q., Li, D., Zhang, J., Piao, Z., Xi, Y., Xi, Y., Kamal, N. N. S. N. M., Li, P., Li, P., & Yin, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102593 · Cited by 19 · see citing works

Triple-mode sensing platform for acetylcholinesterase activity monitoring and anti-Alzheimer's drug screening based on a highly stable Cu (I) compound

Cai, Y., Li, Y., Wang, Y., Xu, Y., Chen, T., Xue, R., Liu, Y., Chen, W., Yang, X., Liu, Z., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.117078 · Cited by 19 · see citing works

The potential role of aryl hydrocarbon receptor in Alzheimer's disease: Protective or detrimental

Al-Kuraishy, H. M., Al-Maiahy, T. J., Sulaiman, G. M., Mohammed, H. A., Albuhadily, A. K., Al-Gareeb, A. I., & Abomughaid, M. M. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102810 · Cited by 19 · see citing works

Sex‐dependent cholinergic effects on amyloid pathology: A translational study

German‐Castelan, L., Shanks, H. R. C., Gros, R., Saito, T., Saido, T. C., Saksida, L. M., Bussey, T. J., Prado, M. A. M., Schmitz, T. W., Prado, V. F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13481 · Cited by 19 · see citing works

Insights into prevention mechanisms of bioactive components from healthy diets against Alzheimer's disease

Wang, J., Yu, Z., Ye, P., & Xu, B. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109397 · Cited by 18 · see citing works

Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease

Aguilar, L. F., Hall, H., Orciani, C., Foret, M. K., Kovecses, O., Ducatenzeiler, A., & Cuello, A. C. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12835 · Cited by 16 · see citing works

Altered levels of variant cholinesterase transcripts contribute to the imbalanced cholinergic signaling in Alzheimer’s and Parkinson’s disease

Gök, M., Madrer, N., Zorbaz, T., Bennett, E. R., Greenberg, D., Bennett, D. A., & Soreq, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.941467 · Cited by 17 · see citing works

Δ8-THC Protects against Amyloid Beta Toxicity Modulating ER Stress In Vitro: A Transcriptomic Analysis

Gugliandolo, A., Blando, S., Salamone, S., Caprioglio, D., Pollastro, F., Mazzon, E., & Chiricosta, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076598 · Cited by 17 · see citing works

Long‐term nucleus basalis cholinergic depletion induces attentional deficits and impacts cortical neurons and BDNF levels without affecting the NGF synthesis

Orciani, C., Hall, H., Pentz, R., Foret, M. K., Carmo, S. D., & Cuello, A. C. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15683 · Cited by 16 · see citing works

Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids

Szczurowska, E., Szánti‐Pintér, E., Chetverikov, N., Randáková, A., Kudová, E., & Jakubík, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010507 · Cited by 14 · see citing works

Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology

Orciani, C., Carmo, S. D., Foret, M. K., Hall, H., Bonomo, Q., Lavagna, A., Huang, C., & Cuello, A. C. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.09.010 · Cited by 14 · see citing works

Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid

Garcia‐Ratés, S., García‐Ayllón, M., Falgàs, N., Brangman, S. A., Esiri, M. M., Coen, C. W., & Greenfield, S. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13869 · Cited by 14 · see citing works

Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up

Knezović, A., & Šalković‐Petrišić, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02887-2 · Cited by 14 · see citing works

Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects

Teitsdottir, U. D., Darreh‐Shori, T., Lund, S. H., Jónsdóttir, M. K., Snædal, J., & Petersen, P. H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.876019 · Cited by 13 · see citing works

Caring for Individuals with Alzheimer’s Disease: A Spotlight on Hispanic Caregivers

Garcia, R. I., Khemka, S., Roghani, A. K., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, A. P., Sehar, U., & Reddy, P. H. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240035 · Cited by 13 · see citing works

Muscarinic Receptors and Alzheimer’s Disease: New Perspectives and Mechanisms

Monaco, M., Trebesova, H., & Grilli, M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070407 · Cited by 13 · see citing works

β-Sitosterol ameliorates the cognitive deficits and neuropathological hallmarks in an Alzheimer’s disease model

Sajad, M., Ali, R., Kumar, R., Khan, N. J., Wahab, S., Alshehri, S. A., & Thakur, S. C. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.106072 · Cited by 13 · see citing works

Chronic inflammation with microglia senescence at basal forebrain: impact on cholinergic deficit in Alzheimer’s brain haemodynamics

Liu, D., Hsueh, S., Tweedie, D., Price, N., Glotfelty, E. J., Lecca, D., Telljohann, R. S., de Cabo, R., Hoffer, B. J., & Greig, N. H. (2024) · Brain Communications · doi:10.1093/braincomms/fcae204 · Cited by 13 · see citing works

Rapid identification of chemical components and screening of acetylcholinesterase inhibitors from Dalbergia odorifera based on mass defect and diagnostic ion filtering strategy, affinity ultrafiltration, and liquid chromatography‐tandem mass spectrometry

Zhang, H., Liu, Y., Zhang, L., Tian, Z., Zhang, H., & Jiang, H. (2024) · Journal of Separation Science · doi:10.1002/jssc.202400288 · Cited by 12 · see citing works

Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease

Benetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 13 · see citing works

Neochlorogenic acid ameliorates Alzheimer's disease-like pathology via scavenging oxidative stress and restoring blood-brain barrier function in zebrafish

Gao, L., Wang, B., Cui, X., Xia, L., Li, X., Núñez-Figueredo, Y., Li, D., Liu, K., Wang, H., & Jin, M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111334 · Cited by 12 · see citing works

Action of the Purinergic and Cholinergic Anti-inflammatory Pathways on Oxidative Stress in Patients with Alzheimer’s Disease in the Context of the COVID-19 Pandemic

Simões, J. L. B., Sobierai, L. D., Leal, I. F., dos Santos, M. V. R., Coiado, J. V., & Bagatini, M. D. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.12.007 · Cited by 11 · see citing works

Recent Progress in the Treatment Strategies for Alzheimer’s Disease

Kumar, V., & Roy, K. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_1 · Cited by 11 · see citing works

Structural and functional remodeling of neural networks in β-amyloid driven hippocampal hyperactivity

Li, J., Liu, Y., Yin, C., Zeng, Y., & Mei, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102468 · Cited by 12 · see citing works

Flavonoids as a phytobiotic agent: sources, classifications, biological benefits, and useful impacts on broilers and layers

El-Hack, M. E. A., Aldhalmi, A. K., Kamal, M., Khafaga, A. F., Moustafa, M., Al-Shehri, M., Świątkiewicz, S., Khalifa, N. E., & Attia, Y. A. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10129-2 · Cited by 11 · see citing works

Nanozyme-based dual-signal sensing system for colorimetric and photothermal detection of AChE activity in the blood of liver-injured mice

He, C., Ke, Z., Liu, K., Peng, J., Yang, Q., Wang, L., Feng, G., & Fang, J. Q. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04663-1 · Cited by 11 · see citing works

Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

Dávila, G., Torres‐Prioris, M. J., López-Barroso, D., & Berthier, M. L. (2023) · CNS Drugs · doi:10.1007/s40263-023-01017-4 · Cited by 10 · see citing works

Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer ’s disease: A systematic review and network meta- analysis

Cao, W., Zhu, B., Liu, Z., Jia, X.-T., Zhao, H., Gu, N., Chang, H., Xi, J., Li, R., Guo, K., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.029 · Cited by 10 · see citing works

Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases

Ishihara, K., Takata, K., & Mizutani, K. (2023) · Life · doi:10.3390/life13010221 · Cited by 10 · see citing works

Ammonium Amphiphiles Based on Natural Compounds: Design, Synthesis, Properties, and Biomedical Applications. A Review

Pashirova, T. N., Shaihutdinova, Z. M., Mironov, V. F., & Bogdanov, A. V. (2023) · Doklady Chemistry · doi:10.1134/s0012500823700179 · Cited by 10 · see citing works

Up-regulation of GPR139 in the medial septum ameliorates cognitive impairment in two mouse models of Alzheimer’s disease

Mu, R.-H., Hou, X., Liu, Q., Wang, W., Qin, C., & Li, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111786 · Cited by 9 · see citing works

Artificial intelligence-driven development of natural multi-target derivatives with BuChE inhibitory activity for treating Alzheimer's disease

Zhang, Q., Li, Y., Jin, Q., Liu, Z., Chen, H., Huang, J., Liu, T., Liu, X., Tan, Z., Huang, S., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110964 · Cited by 8 · see citing works

The involvement of the cholinergic system in Alzheimer disease

Cuello, A. C. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19088-9.00005-6 · Cited by 8 · see citing works

Single‐nucleus analysis reveals oxidative stress in Down syndrome basal forebrain neurons at birth

West, N. R., Arachchilage, K. H., Knaack, S., MacGregor, S., Hosseini, M., Risgaard, R. D., Kumarage, P., Martinez, J. L., Zhang, S., Wang, D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70445 · Cited by 8 · see citing works

Synthesis, Biological Evaluation and Machine Learning Prediction Model for Fluorinated Cinchona Alkaloid-Based Derivatives as Cholinesterase Inhibitors

Ramić, A., Matošević, A., Debanić, B., Mikelić, A., Primožič, I., Bosak, A., & Hrenar, T. (2022) · Pharmaceuticals · doi:10.3390/ph15101214 · Cited by 8 · see citing works

Effect of APOE4 Allele and Gender on the Rate of Atrophy in the Hippocampus, Entorhinal Cortex, and Fusiform Gyrus in Alzheimer's Disease.

Hamza, E., Moustafa, A. A., Tindle, R., Karki, R., Nalla, S., Hamid, M. S., & el Haj, M. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230309113749 · Cited by 8 · see citing works

Rethinking early Alzheimer’s disease: An impaired internal model updating disorder?

Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 7 · see citing works

Histamine H1 receptors in dentate gyrus-projecting cholinergic neurons of the medial septum suppress contextual fear retrieval in mice

Li, C., Xiao, L., Lin, W., Li, M., Liu, J., Qiu, X., Li, M., Zheng, Y., Xu, C., Wang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50042-4 · Cited by 6 · see citing works

Deciphering the Functions of Raphe–Hippocampal Serotonergic and Glutamatergic Circuits and Their Deficits in Alzheimer’s Disease

Yu, W., Zhang, R., Zhang, A., & Mei, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031234 · Cited by 7 · see citing works

Insight into JNK Inhibition-based Strategy for the Treatment of Alzheimer's Disease

Zyuz’kov, G. N., Miroshnichenko, L. A., Polyakova, T. Y., Simanina, E. V., Chaikovskii, A. V., & Kotlovskaya, L. Y. (2023) · Current Enzyme Inhibition · doi:10.2174/1573408019666230816143357 · Cited by 7 · see citing works

Exploring the potential mechanism of Polygonatum sibiricum for Alzheimer’s disease based on network pharmacology and molecular docking: An observational study

Luo, L., Pan, Y., Chen, F., & Zhang, Z. (2024) · Medicine · doi:10.1097/md.0000000000040726 · Cited by 6 · see citing works

The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status

Liu, W., Li, Y., Qin, W., Wang, X., Li, W., Li, Y., Initiative, A. D. N., & Jia, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70193 · Cited by 6 · see citing works

Evaluation of vascular cognitive impairment and identification of imaging markers using machine learning: a multimodal MRI study

He, H., Lu, D., Peng, S., Jiang, J. C., Fan, F., Sun, D. B., Sun, T., Xu, Z., Zhang, P., Peng, X., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1505739 · Cited by 6 · see citing works

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors

Benetik, S. F., Proj, M., Knez, D., Košak, U., Meden, A., Krajšek, K., Pišlar, A. H., Horvat, S., Švajger, U., Tešić, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00933 · Cited by 6 · see citing works

Carltonine-derived compounds for targeted butyrylcholinesterase inhibition

Pidaný, F., Křoustková, J., Jenčo, J., Breiterova, K. H., Múčková, Ľ., Novakova, L., Kuneš, J., Fibigar, J., Kucera, T., Novak, M., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00060a · Cited by 6 · see citing works

LINC00472 Regulates Ferroptosis of Neurons in Alzheimer’s Disease via FOXO1

Lin, P., Wang, J., Li, Y., Li, G., & Wang, Y. (2024) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000537883 · Cited by 6 · see citing works

Neuroprotective effects of Anshen Bunao Syrup on cognitive dysfunction in Alzheimer's disease rat models

Sun, Y., Xia, Q., Du, L., Gan, Y., Ren, X., Liu, G., Wang, Y., Yan, S., Li, S., Zhang, X., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116754 · Cited by 6 · see citing works

Interactions of memantine and rivastigmine with graphene oxide nanocarrier and beta-amyloid protein using molecular docking and in-silico methods

Davoudi, F., Shadjou, N., & Darroudi, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37702 · Cited by 6 · see citing works

Current Status of Plant-Based Bioactive Compounds as Therapeutics in Alzheimer’s Diseases

Chen, D., & Sun, Y. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin23090 · Cited by 6 · see citing works

Role of Pyrazole Moiety in the Treatment of Alzheimer's Disease: A Comprehensive Review of Various Synthetic Routes and Probable Mechanisms of Action

Thakur, A., Singh, R., Mehta, V., & Paliwal, D. (2025) · ChemistrySelect · doi:10.1002/slct.202500130 · Cited by 6 · see citing works

Structure−activity relationship of ginsenoside derivatives with different glycosides and double bond position on anti-aging bioactivities

Zhang, J., Wang, W., Fan, D., Deng, J., & Yang, H. (2025) · Journal of Ginseng Research · doi:10.1016/j.jgr.2025.05.002 · Cited by 5 · see citing works

The Central Cholinergic Synapse: A Primer

Klein, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199670 · Cited by 5 · see citing works

The therapeutic potential of early exercise in Alzheimer's disease: Focus on the brain-spleen axis

Wang, T., Feng, L., & Tian, Z. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102980 · Cited by 6 · see citing works

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

Ferreira, D., Chmiela, T., Eriksdotter, M., Jack, C. R., Kalpouzos, G., Marseglia, A., Mecocci, P., Nordberg, A. K., Religa, D., & Westman, E. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70096 · Cited by 7 · see citing works

Plantainoside B in Bacopa monniera Binds to Aβ Aggregates Attenuating Neuronal Damage and Memory Deficits Induced by Aβ

Fukuda, A., Nakashima, S., Oda, Y., Nishimura, K., Kawashima, H., Kimura, H., Ohgita, T., Kawashita, E., Ishihara, K., Hanaki, A., et al. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00797 · Cited by 5 · see citing works

Anxiolytic, Antidepressant, and Anticholinesterase Effects of Essential Oil from Myrcia sylvatica (G.Mey.) DC

Júnior, A. Q. D. S., Garcia, M. M., Farias, W. D. S., de Sousa, D. J. D. A., Barroso, A. D. S., Figueiredo, P. L. B., dos Santos, G. B., de Oliveira, R. B., & Mourão, R. H. V. (2025) · Biomolecules · doi:10.3390/biom15010110 · Cited by 5 · see citing works

Ameliorative effects of thiamin on learning behavior and memory dysfunction in a rat model of hypothyroidism: implication of oxidative stress and acetylcholinesterase

Saberi, R., Mirazi, N., Amirahmadi, S., Darbandi, Z. K., Vafaee, F., Rajabian, A., & Hosseini, M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01317-0 · Cited by 5 · see citing works

The novel orthosteric agonist M1 muscarinic acetylcholine receptor reveals anti-Alzheimer’s disease activity

Taheri, M., Mehr, M. A., & Ghafouri, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-80102-0 · Cited by 5 · see citing works

dyphAI dynamic pharmacophore modeling with AI: a tool for efficient screening of new acetylcholinesterase inhibitors

Hayek-Orduz, Y., Castro, D. A. A., Escobar, J. S. S., Ortiz-Domínguez, B. E., Villegas-Torres, M. F., Caicedo, P. A., Barrera-Ocampo, A. A., Cortés, N., Osorio, E. H., & Barrios, A. F. G. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1479763 · Cited by 5 · see citing works

The unsafe profile of lecanemab

Høilund‐Carlsen, P. F., Werner, T. J., & Alavi, A. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251325891 · Cited by 5 · see citing works

Age‐Dependent Regulation of Hippocampal Inflammation by the Mitochondrial Translocator Protein in Mice

Lai, K. O., Wong, J. H., Tham, N., Fairley, L. H., Naik, R. R., Wang, Y., Langley, S. R., & Barron, A. M. (2025) · Aging Cell · doi:10.1111/acel.70039 · Cited by 4 · see citing works

Cognition and modulation of the cholinergic system

Snyder, P. J., & Maruff, P. T. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19088-9.00012-3 · Cited by 4 · see citing works

Evaluation of the Alterations in Central Cholinergic Neurotransmission in Aging and Amyloid Precursor Protein Knock‐In Mice

Nagai‐Arakawa, I., Muramatsu, I., Uwada, J., Tsuda, Y., Tokunaga, A., Irie, A., Maeda, H., Madokoro, Y., Sato, T., Uchida, Y., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70081 · Cited by 4 · see citing works

Stimulation of α7 Nicotinic Acetylcholine Receptors by PNU282987 Demonstrates Efferocytosis-Like Activation and Neuroprotection in Human Models of Microglia and Cholinergic Neurons under the Pathophysiological Conditions of Alzheimer’s Disease

Sueyoshi, M., Harada, K., Okawa, M., Matsuhara, T., Ando, M., Araki, R., Minote, Y., Ishihara, K., Shimohama, S., & Takata, K. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00308 · Cited by 4 · see citing works

MiR-153 Prevents NRF2 Nuclear Translocation to Drive Hypoperfusion-Related Cognitive Deficits by Targeting KPNA5

Qu, Y., Wu, Y., Xu, X., Cheng, W., Zhang, L., Ma, J., Xu, W., Chen, M., Cong, G., Liu, J., et al. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2148-24.2025 · Cited by 4 · see citing works

The Janus face of CaMKII: from memory consolidation to neurotoxic switch in Alzheimer’s disease

Tang, L., Liu, F., Sun, X., Yang, J., Liu, Y., Pan, X., Hao, L., Lou, F., & Su, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04160-7 · Cited by 5 · see citing works

Dysregulated mTOR signaling in Alzheimer's disease: Linking pathogenic mechanisms to emerging therapeutic strategies

Zhang, S., Wang, T., Gu, X. F., Zheng, R., Ding, N., Yang, J., & Zhang, M. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251400667 · Cited by 5 · see citing works

Advances in ultrasensitive detection technologies for blood-based biomarkers of Alzheimer's disease

Mou, Y., Sun, C., Deng, K., Lin, F., Yang, Z., Wang, Y., Deng, X., Yang, F., Hu, X., & Jiang, Q. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02633d · Cited by 4 · see citing works

Targeting Adenylate Cyclase: A Novel Concept for Stimulation of Neurogenesis and Pharmacotherapy of Alzheimer's Disease

Zyuz’kov, G. N., Miroshnichenko, L. A., Polyakova, T. Y., Simanina, E. V., & Chaikovskii, A. V. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249302264240715060630 · Cited by 4 · see citing works

Cholinergic system in patients with chronic kidney disease: cognitive and renal implications

Xu, H., Eriksdotter, M., Hafez, G., Mitra, S., Bruchfeld, A. N., Pešić, V., Unwin, R. J., Wagner, C. A., Massy, Z. A., Zoccali, C., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf029 · Cited by 4 · see citing works

Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer’s Disease

Kamkwalala, A. R., & NEWHOUSE, P. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112625 · Cited by 53 · see citing works

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease

Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · see citing works

Cholinergic Treatments with Emphasis on M1 Muscarinic Agonists as Potential Disease-Modifying Agents for Alzheimer's Disease

Fisher, A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.002 · Cited by 151 · see citing works

Drugs That Stimulate Cholinergic

Agonists, M. (2016)

The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings

Frölich, L. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200083 · Cited by 94 · see citing works